Prothena Corporation plc Stock Price and Value Analysis

Prothena Corporation plc (NasdaqGS:PRTA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Prothena Corporation plc to reach your target.

Target type

PRTA Free Cash Flow Trend

Free Cash Flow trendline for PRTA
Free Cash Flow trendline for Prothena Corporation plc

Hmm, we can't give any reliable projection for Prothena Corporation plc's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the PRTA Numbers

PRTA Price
(Prothena Corporation plc stock price per share)
$8.35
[?] PE Ratio versus Sector 2% lower than other Healthcare stocks
[?] PE Ratio versus Industry 65% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 83%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Prothena Corporation plc's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-05-06 EcoR1 Capital, LLC Sell 1,984,053 $7.64
2025-05-05 EcoR1 Capital, LLC Sell 977,693 $8.11
2025-05-02 EcoR1 Capital, LLC Sell 3,317,938 $8.36
2025-01-14 SCULLY WILLIAM P Buy 100,000 $12.79
2024-12-31 SCULLY WILLIAM P Buy 1,200 $13.37
2024-12-31 SCULLY WILLIAM P Buy 800 $13.39
2024-12-31 SCULLY WILLIAM P Buy 30,000 $12.99
2024-12-20 SCULLY WILLIAM P Buy 2,000 $15.91
2024-12-18 SCULLY WILLIAM P Buy 73,436 $13.93

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,911,160 shares shorted. With 34,189,208 shares available for purchase and an average trading volume over the past 10 trading days of 424,960, it would take at least 18.6 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Cash Conversion

Over the 1 fiscal years from 2011 to 2025 with positive net income, operating cash flow totaled $92.6 million against net income of $67.0 million, or 1.38 times. Net income was negative in 14 of the 15 years, and those years are left out of the ratio.

In 2025, net income was -$244.1 million and operating cash flow was -$163.6 million, so no ratio is shown for that year.

In 2021, capital expenditures were $0.6 million, 0.6% of operating cash flow of $92.6 million, which leaves an estimated $92.0 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 -29.7 -19.7 0.6 n/a
2012 -41.4 -42.1 1.3 n/a
2013 -41.0 -32.1 0.6 n/a
2014 -7.2 -0.7 0.5 n/a
2015 -80.6 -58.6 1.4 n/a
2016 -160.1 -116.2 16.6 n/a
2017 -153.2 -131.2 3.6 n/a
2018 -155.6 -28.3 1.8 n/a
2019 -77.7 -53.0 0.6 n/a
2020 -111.1 -80.4 0.2 n/a
2021 67.0 92.6 0.6 1.38
2022 -116.9 -108.8 0.5 n/a
2023 -147.0 -133.9 2.8 n/a
2024 -122.3 -150.1 0.3 n/a
2025 -244.1 -163.6 0.1 n/a

Revenue and Cash Margin

Revenue was $2.7 million in 2012 and $9.7 million in 2025, a compound annual growth rate of 10.5% over 13 years.

Revenue fell 92.8% from 2024 to 2025.

Our estimated free cash flow was -$164.4 million in 2025, a negative margin of 1698.0% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 1618.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 2.7 -43.0 -1618.5%
2013 0.7 -32.9 -4869.5%
2014 50.9 -1.4 -2.8%
2015 1.6 -59.5 -3700.9%
2016 1.1 -120.3 -11406.0%
2017 27.5 -135.7 -493.2%
2018 1.0 -33.1 -3462.3%
2019 0.8 -57.8 -7096.3%
2020 0.9 -84.9 -9955.4%
2021 200.6 91.3 45.5%
2022 53.9 -109.5 -203.2%
2023 91.4 -134.8 -147.6%
2024 135.2 -150.9 -111.7%
2025 9.7 -164.4 -1698.0%

Balance Sheet

In 2025, cash and equivalents were $307.5 million against total liabilities of $46.3 million, or 663.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 14.2% of total assets in 2025, compared with 2.2% in 2012, an increase of 12.0 percentage points.

Stockholders equity was $280.5 million in 2025, compared with $126.5 million in 2012, a rise of 121.7%.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2012 129.3 124.9 2.8 126.5
2013 182.4 176.7 9.1 173.3
2014 304.1 293.6 14.2 289.9
2015 385.2 370.6 24.6 360.7
2016 460.0 386.9 94.6 365.4
2017 496.3 417.6 89.1 407.2
2018 498.8 427.7 175.8 323.0
2019 419.3 375.7 146.3 272.9
2020 333.0 295.4 149.0 184.0
2021 609.4 579.1 143.3 466.0
2022 758.0 710.4 136.0 622.0
2023 696.4 618.8 135.0 561.4
2024 547.1 471.4 60.2 486.9
2025 326.8 307.5 46.3 280.5

Price Versus Our Estimated Value

Only 1 of the 15 fiscal years under Prothena Corporation plc's current filer show positive free cash flow.

We do not estimate a fair value for Prothena Corporation plc while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 83%.

Dividends are not in our data for Prothena Corporation plc.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

Its trailing P/E ratio is 2% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 65% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1559053.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 14 of the 15 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in PRTA

Does Prothena Corporation plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: PRTA

This example shows how we apply the Trendshare checklist to PRTA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 8.35
    • Market cap: $429M
    • EPS: -0.45
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.